Switching from intravenous to subcutaneous infliximab in hidradenitis suppurativa: A French multicenter retrospective study

Infliximab is used off-label in moderate-to-severe hidradenitis suppurativa (HS).1,2 A subcutaneous (SC) formulation is now available for rheumatoid arthritis, inflammatory bowel disease, axial spondyloarthritis and psoriasis. As it is used off label in HS, data on switching from IV to SC infliximab are lacking. We conducted a retrospective multicenter study across 8 French dermatology centers. All HS patients switched from IV to SC infliximab between August 2021 and October 2025 were included. The decision to switch from IV to SC infliximab was made at the attending physician's discretion.